Bristol-Myers Squibb Company (BMY) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Margins ⢠Heavy Leverage ⢠Solid Dividend BMY shows strong profitability and cash generation with solid dividend coverage, but elevated leverage and modest liquidity keep the risk profile mixed.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Resistance Capping ⢠Failed Breakout Support Level: $57.67â$58.00 Resistance Level: $59.5â$61.1 BMY has been range-bound over the last month, holding near support in the high-$57s to $58 while repeatedly failing to break through resistance around $59.5â$61, leaving the short-term trend neutral to slightly weak.
Sentiment & News
Key News Insights: ⢠Growth mix shift ⢠Generic pressure ⢠Mixed sentiment Bristol Myers Squibb's headlines point to improving growth-drug momentum and investor support, but near-term revenue and earnings remain pressured by legacy drug and generic declines.
AI Summary
BMY is now best viewed as a cash-rich turnaround rather than a steady pharma compounder: strong free cash flow and a credible pipeline can support the dividend and balance sheet, but the stock hinges on whether new growth franchises scale fast enough to offset 2026 legacy-drug and generic pressure before leverage and binary clinical risk cap upside.
Description
Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, licenses, manufactures and markets medicines across oncology, hematology, cardiovascular, immunology, fibrosis, neuroscience and infectious disease. Its commercial portfolio includes oral and biologic therapies for cancer, cardiovascular and immune-mediated conditions, with widely used products such as Eliquis and Opdivo, and it sells through wholesalers, pharmacies, hospitals and government channels. Founded in 1887, the company is headquartered in New York, New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 9 | Feb 16 | BMY | Bristol-Myers Squibb Company | Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days. | Closed | -0.1% |
| Dec 23 | Dec 30 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb (BMY) benefits from 17% Q3 portfolio growth, upcoming FDA review and clinical data catalysts, strong operational turnaround with positive earnings and cash flow, and sustained 17% stock gain over 21 days with technical momentum. Its diversified oncology portfolio and dividend appeal underpin a strong near-term growth case. | Closed | -0.1% |
| Dec 4 | Dec 11 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb shows compelling near-term upside with strong Q3 revenue and raised guidance, notable clinical/regulatory catalysts (FDA Fast Track, Phase 3 trials), substantial debt reduction, and technical breakout signaling positive momentum. | Closed | -1.4% |